Resistência ao hormônio tireoidiano detectada por meio da triagem neonatal by MACIEL, Léa Maria Zanini & MAGALHÃES, Patrícia Künzle Ribeiro
Co
py
rig
ht
©
 A
BE
&
M
 to
do
s o
s d
ire
ito
s r
es
er
va
do
s.
723Arq Bras Endocrinol Metab. 2010;54/8
clinical case report
Thyroid hormone resistance detected 
by routine neonatal screening
Resistência ao hormônio tireoidiano detectada 
por meio da triagem neonatal
Léa Maria Zanini Maciel1, Patrícia Künzle Ribeiro Magalhães1
SUMMARY
We report the clinical and laboratory findings, and molecular analysis of a Brazilian patient with 
resistance to thyroid hormone syndrome (RTH) detected by neonatal screening. The index case 
was born at term by normal delivery with 2,920 g and 45 cm. TSH of the neonatal screening test 
performed on the 5th day of life was of 13.1 μU/mL (cut-off = 10 μU/mL). In a confirmatory test, 
serum TSH level was 4.3 μU/mL, total T4 was 19 μg/dL (confirmed in another sample, Total T4 = 
> 24.0 μg/dL), free T4 was 3.7 ηg/dL, and free T3 was 6.7 pg/mL. Direct sequencing of the beta 
thyroid hormone receptor gene revealed mutation c.1357C>A (P453T), confirming the diagnosis 
of RHT. Family study demonstrated the presence of RTH in his 1-year-and-3-month-old sister, 
in his 35-year-old father, and in his 68-year-old paternal grandfather. All of them had goiter 
and only his father had received an erroneous diagnosis of hyperthyroidism. The present case 
shows that clinical evaluation and a judicious interpretation of total T4/free T4 concentrations in 
a newborn recalled due to slightly altered neonatal TSH can contribute to the diagnosis of RTH. 
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SUMÁRIO
O objetivo deste estudo é relatar o caso de um paciente brasileiro com resistência ao hormô-
nio tireoidiano (RTH) detectado por meio da triagem neonatal. O caso índice nasceu de parto 
normal a termo com peso de 2.920 g e estatura de 45 cm. Realizou o teste de triagem neonatal 
no quinto dia de vida com TSH neonatal = 13,1 μU/mL (valor de corte = 10 μU/mL). O TSH con-
firmatório no soro foi de 4,3 μU/mL, T4 Total de 19 μg/dL (confirmado em outra amostra, T4 Total 
= > 24,0 μg/dL), T4 Livre de 3,7 ηg/dL e T3 Livre de 6,7 pg/mL. O sequenciamento direto do gene 
do receptor b do hormônio tireoidiano revelou a mutação c.1357C>A (P453T), confirmando o 
diagnóstico de RHT. O estudo de sua família confirmou RTH em sua irmã (1 ano e 3 meses), 
em seu pai (35 anos) e em seu avô paterno (68 anos). Todos apresentavam bócio e apenas seu 
pai havia recebido o diagnóstico errôneo de hipertireoidismo. Este caso ilustra que a avaliação 
clínica e a interpretação criteriosa das concentrações de T4 Total/Livre em um recém-nascido, 
reconvocado por TSH neonatal discretamente alterado, poderão servir para o diagnóstico da 
RTH. Arq Bras Endocrinol Metab. 2010;54(8):723-7
1 Division of Endocrinology, 
Department of Clinical Medicine, 
Faculdade de Medicina de 
Ribeirão Preto, Universidade 
de São Paulo (FMRP-USP), 
Ribeirão Preto, SP, Brazil
Correspondence to:
Léa Maria Zanini Maciel
Av. Bandeirantes, 3900
14049-900 − Ribeirão Preto, SP, 
Brazil
lmzmacie@fmrp.usp.br
Received on Jul/16/2010
Accepted on Nov/15/2010
IntROdUCtIOn
The resistance to thyroid hormone syndrome (RTH) is an inherited disease that is usually suspected when 
elevated serum thyroid hormone (TH) levels are associ-
ated with non-suppressed thyrotropin (TSH). There are 
no pathognomonic clinical findings for RTH; frequen-
tly, thyroid function tests are requested based on short 
stature, hyperactivity, and goiter are noted in children 
and adolescents (1).
We report a patient with RTH suspected at birth 
by analysis of blood obtained during routine neonatal 
screening. A later study of his family permitted the iden-
tification of other affected members.
CASE REPORt
The propositus was born at term by normal delivery 
(birth weight: 2,950 g; birth length: 45 cm; head cir-
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cumference at birth: 32 cm; 5’ Apgar score = 9) with no 
untoward postnatal events, except for jaundice which 
regressed spontaneously. He was discharged from the 
hospital within 48 hours. A neonatal screening test was 
performed at day 5 of life and TSH was measured in a 
heel prick dried blood spot. TSH result was 13.1 μIU/
mL of blood, above the cut-off level (10 μIU/mL), 
and the infant was called for evaluation. 
Clinical evaluation at 15 days of life revealed that 
the infant’s weight was 3,280 g and his height was 50.5 
cm. He was in good general conditions, with jaundice 
(zone II), heart rate (HR) of 140 bpm, anterior fon-
tanelle of 3 x 2 cm and posterior fontanelle of 1.5 cm; 
goiter was absent on palpation. 
Family history: the mother, a healthy 19-year-old 
woman, had an uneventful pregnancy and did not use 
medications. She reported a previous pregnancy 1 year 
and 3 months earlier, also uneventful. The father, a 
35-year-old man, reported that he had started to have 
tremors, nervousness, fatigue, asthenia, palpitations dur-
ing exercise, hyperdefecation and insomnia since age 20. 
He denied goiter, exophthalmia or changes in weight. 
He consulted with a doctor who performed blood tests 
and thyroid scintigraphy with the detection of thyroid 
disorder and prescription of antithyroid medication. He 
used the medication for one month and discontinued 
treatment by choice. Examination revealed a diffusely 
enlarged thyroid (3 times the normal size). The father 
reported that his paternal grandmother had a large goi-
ter and that she had died at age 58, on the occasion of 
a thyroidectomy. He has 3 living siblings, but he has no 
information about their health conditions. The sister of 
the index case, evaluated at 1 year and 11 months of 
age, was born at term by normal delivery with a birth 
weight of 2,225 g and a birth length of 45 cm. She 
was submitted to a neonatal screening test for which the 
result obtained was normal. She walked at the age of 1 
year and 3 months. According to her parents, the child 
is very agitated and nervous. Examination revealed the 
presence of goiter (thyroid twice the normal size), HR 
of 124 bpm, and increased skin temperature and mois-
ture. Weight = 9.4 kg (P3); height = 84 cm (P50). 
Laboratory tests for the whole family are listed in 
table 1 and were compatible with RTH. 
In view of these results, the paternal grandfather of 
the index case was called for an evaluation. A retired ru-
ral worker, at 68 years of age he was in good health and 
had not noticed his goiter, even though it was visible 
upon clinical examination. His HR was 72 bpm and 
his thyroid was diffusely enlarged (3 times the normal 
size), with an irregular surface. His lab tests were also 
compatible with RTH (TSH = 4.4 μIU/mL, FT4 = 2.6 
ng/dL; FT3 = 5.4 pg/mL) (Table 1).
Molecular study of the family was performed by 
genomic extraction of peripheral blood DNA using a 
previously described method (2). Exons 7, 8, 9, and 10 
of the thyroid hormone receptor b gene (TRb) were 
amplified by polymerase chain reaction (PCR), using 
as primers oligonucleotide sequences based on the nor-
mal sequence of the TRb gene (2).The study revealed 
a missense mutation in exon 10, in which a cytosine-
adenine substitution in nucleotide 1357 (codon 453) 
caused a proline-threonine substitution (p.P453T), 
confirming the diagnosis of RTH (Figure 1).
Family pedigree is presented in figure 2.
Analytical methods
Neonatal TSH determination was done by time-re-
solved fluoroimmunoassay (AutoDELFIA neoTSH 
assay from PerkinElmer Wallac, Turku, Finland) and 
serum TT4, FT4, FT3 and TSH were measured by che-
miluminescent method (Immulite, DPC Cirrus Inc., 
Los Angeles, CA, USA). 
The study protocol was approved by the ethics 
committee of the University Hospital of the School of 
Medicine of Ribeirão Preto – University of São Paulo. 
Consent was obtained from the proband’s parents and 
from his relatives.
table 1. Laboratory profile of the case study family with resistance to thyroid hormone
Age tSH(µIU/mL) Free t4 (ng/dL) total t4 (µg/dL)
Free t3
(pg/mL)
Index case 15 days 4.3 3.7 19.0* 6.7
Sister 23 months 5.6 3.5 17.3 10.3
Father 35 years 3.0 3.1 18.3 6.0
Grandfather 68 years 5.3 2.4 - 4.4
Reference values for adults: TSH: 0.4-4.0 µIU/mL; Free T4: 0.8-1.8 ng/dL; Free T3: 1,5-4.1 pg/mL; Total T4: 4.5-12.5 µg/dL. Reference Values for 7-30 days of age: TSH: 0.5-4.6 µIU/mL; Free T4: 1.8-2.9 
ng/dL; Free T3: 2.7-4.6 pg/mL. * Results of other determinations: Total T4 ≥ 24.0 µg/dL, 22.2 µg/dL.
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Figure 2. Pedigree of the case study family with thyroid hormone resistance 
(RTH). Circles: females; squares: males. Shaded symbols indicate the 
confirmation of the mutation. The arrow indicates the index case. Roman 
numerals identify the generation and Arabic numerals identify the 
individual. A line through the symbols indicates that the subject is 
deceased. An asterisk “*” indicates that blood was obtained from subject 
for analysis. Individual I2 died during surgery for goiter removal, possibly 
the 4th generation ancestors of the propositus also had RTH.
Figure 1. Electropherogram obtained by sequencing PCR fragments of the 
b gene for thyroid hormone receptor, showing the c.1357C>A missense 
mutation (P453T) in heterozygosis in the index case. The same mutation 
was found in the other members of the family (index case’s sister, father and 
grandfather). The arrows indicate the position of the mutation.
dISCUSSIOn
We report a Brazilian patient with RTH due to muta-
tion c.1357C>A detected by neonatal screening.
In Brazil, the newborn screening program starts 
with the measurement of TSH in a blood spot dried 
on filter-paper and the cut-off level at our center is 10 
μU/mL. The propositus presented a neonatal TSH = 
13.1 μU/mL and he was recalled for evaluation. Con-
firmatory serum TSH had normalized, but serial thy-
roid function tests continued to show elevated serum 
total and free T3 and T4 levels, above the normal limits 
for his age. Among persistent hyperthyroxinemia disor-
ders, neonatal Graves’ disease is the most prevalent and 
its occurrence is estimated at 1 in 10,000 to 50,000 
newborn infants (3,4). Usually the mothers are already 
known to have Graves’ disease, even though thyrotoxi-
cosis has been linked to reduced fertility in women (5). 
Antithyroid drugs cross the placenta to the fetus and, 
depending on the dose, newborn infants can have tran-
sient hypothyroidism until they metabolize and excrete 
the drug. 
Congenital hyperthyroidism resulting from activat-
ing mutations of the TSH receptor has been reported 
(6,7). Although these infants have clinical features of 
hyperthyroidism and goiter, this diagnosis was not 
reported at newborn screening, but the probably el-
evated neonatal T4 concentrations might have been 
detected by screening. Twenty to forty-two percent 
of children with McCune-Albright, a syndrome re-
sulting from somatic cell mutations of the G-protein 
α-subunit within the thyroid (8,9), have also been re-
ported to develop hyperthyroxinemia during the neo-
natal period, and hyperthyroidism present at birth has 
been reported in at least 2 cases (10-12). Other causes 
of hyperthyroxinemia are thyroxine-binding globulin 
(TBG) excess, familial dysalbuminemic hyperthyroxin-
emia (FDH), and RTH. Familial TBG excess, an X-
linked disorder, is estimated to occur in approximate-
ly 1 in 25,000 individuals (13). Patients with FDH 
usually show normal free T4 levels, but free T4 levels 
can be artificially increased when they are measured 
by standard immunoassay methods (14). The patients 
present no signs or symptoms of hyperthyroidism in 
these two situations.
RTH has been detected prenatally in an infant 
whose mother was known to carry the disease (15). 
A few babies have been studied during the neonatal 
period (16) and the biochemical picture seen at birth 
appears to be similar to that found in adulthood. Thus, 
RTH newborns can present with either borderline-ele-
vated (16) or high TSH concentrations (17) associated 
with increased total and free T4 and T3 levels. Current 
screening programs for congenital hypothyroidism are 
not appropriate for an early detection of RTH since as 
they usually measure TSH in dried blood spots. 
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Reports regarding the differential diagnosis of neo-
natal hyperthyroxinemia detected by neonatal screen-
ing are rare (18). Lafranchi and cols. (18) reported the 
first systematic study regarding neonatal screening for 
hyperthyroxinemia. They conducted a follow-up study 
of 80,884 infants screened in Oregon over a 20-month 
period. Enrolling 101 children with a T4 result > 3.0 
SD, they detected 17 with persistent hyperthyroxin-
emia. Ten out of seventeen were considered to have 
TBG excess (elevated serum total T4 and T3 values 
with normal free T4, free T3, and TSH levels) and 
5 of them who were tested showed increased serum 
TBG concentrations. Some of the 5 infants without 
TBG measurements were considered to have increased 
serum T4 binding other than TBG excess, therefore 
probably the FDH disorder. Two infants with elevated 
serum total and free T4 and T3 without suppressed 
TSH were considered to have RTH and a T3b receptor 
gene mutation was identified in one of them. No case 
of neonatal Graves’ disease was detected in that study. 
The authors attributed the absence of neonatal Graves’ 
disease patients to the diagnosis and antithyroid drug 
treatment of pregnant women with Graves’ disease. 
The failure of Lafranchi and cols. (18) to detect cases 
of hyperthyroidism as a result of McCune-Albright syn-
drome or activating TSH receptor mutation is in agree-
ment with the current estimates of the rare occurrence 
of these disorders. 
Recently, Tajima and cols. (19) analyzed 83,232 
newborns screened in Sapporo city, Japan, and detect-
ed 11 infants with persistent hyperthyroxemia. Eight 
patients were diagnosed as having Graves’ disease, 7 
out of 8 pregnant women were treated with antithy-
roid drug and only one unrecognized Graves’ disease 
during pregnancy was detected by the screening. One 
patient with slightly elevated free T4 and normal TSH 
was diagnosed as having familial FDG. The other two 
patients with elevated free T4 without suppressed TSH 
were considered to have RTH and analysis of the thy-
roid hormone receptor b gene confirmed the diagnosis. 
In the present case report, we were able to detect an 
infant with RTH syndrome because his neonatal TSH 
obtained from a dried blood spot was above our cut-
off level. The confirmatory serum TSH was normal for 
his age but his persistently elevated levels of total and 
free T3 and T4 required further investigation. A careful 
analysis of his family led us to suspect the diagnosis of 
RTH. His sister presents clinical characteristics attribut-
able to RTH: she is thin, hyperkinetic and has goiter. 
His father also has goiter and a history of treatment for 
thyrotoxicosis. As mentioned in previous studies (2), 
an erroneous diagnosis of thyrotoxicosis is not infre-
quent in RTH patients. The high thyroid iodine uptake 
associated with clinical signs and symptoms compat-
ible with thyrotoxicosis, frequently leads to erroneous 
treatment with antithyroid drugs and/or radioactive 
iodine. His paternal grandfather had not noticed goiter. 
A very simple retired rural worker, he mentioned that 
his mother had died during surgery for goiter removal. 
Thus, possibly 4th generation ancestors of the proposi-
tus also had RTH.
In conclusion, this case report shows that clinical 
evaluation and judicious interpretation of total T4 and 
free T4 concentrations in a newborn recalled due to 
slightly altered neonatal TSH can contribute to the di-
agnosis of RTH.
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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